The vasopeptidase inhibitor AVE7688 ameliorates Type 2 diabetic nephropathy

MLA

Wolfgang Linz, et al. “The Vasopeptidase Inhibitor AVE7688 Ameliorates Type 2 Diabetic Nephropathy.” Diabetologia, vol. 47, Jan. 2004, pp. 98–103. EBSCOhost, https://doi.org/10.1007/s00125-003-1264-8.

APA

Wolfgang Linz, Hartmut Rütten, Markus Bleich, H. Vollert, Andreas E. Busch, Stefan Schäfer, & G. Biemer-Daub. (2004). The vasopeptidase inhibitor AVE7688 ameliorates Type 2 diabetic nephropathy. Diabetologia, 47, 98–103. https://doi.org/10.1007/s00125-003-1264-8

Chicago

Wolfgang Linz, Hartmut Rütten, Markus Bleich, H. Vollert, Andreas E. Busch, Stefan Schäfer, and G. Biemer-Daub. 2004. “The Vasopeptidase Inhibitor AVE7688 Ameliorates Type 2 Diabetic Nephropathy.” Diabetologia 47 (January): 98–103. doi:10.1007/s00125-003-1264-8.